Trevena Inc (TRVN) Receives Consensus Recommendation of “Buy” from Analysts

Trevena Inc (NASDAQ:TRVN) has been given a consensus rating of “Buy” by the eleven ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $7.35.

A number of research analysts recently commented on the company. Barclays cut Trevena from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $15.00 to $2.50 in a research report on Monday, October 16th. Zacks Investment Research upgraded Trevena from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a research report on Wednesday, October 18th. Oppenheimer restated a “buy” rating and issued a $5.00 price target on shares of Trevena in a research report on Monday, November 13th. Needham & Company LLC decreased their price target on Trevena from $9.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday, November 8th. Finally, HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Trevena in a research report on Wednesday, November 8th.

Trevena (NASDAQ:TRVN) opened at $1.75 on Tuesday. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.92 and a quick ratio of 4.92. Trevena has a 12-month low of $1.34 and a 12-month high of $7.99. The company has a market capitalization of $101.55, a price-to-earnings ratio of -1.06 and a beta of -0.51.

Large investors have recently added to or reduced their stakes in the stock. Nationwide Fund Advisors boosted its stake in Trevena by 92.1% in the second quarter. Nationwide Fund Advisors now owns 49,132 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 23,557 shares in the last quarter. Alliancebernstein L.P. boosted its stake in Trevena by 51.9% in the second quarter. Alliancebernstein L.P. now owns 55,300 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 18,900 shares in the last quarter. Virtu KCG Holdings LLC boosted its stake in Trevena by 144.0% in the second quarter. Virtu KCG Holdings LLC now owns 58,660 shares of the biopharmaceutical company’s stock valued at $135,000 after buying an additional 34,618 shares in the last quarter. Rhumbline Advisers boosted its stake in Trevena by 30.1% in the second quarter. Rhumbline Advisers now owns 64,251 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 14,880 shares in the last quarter. Finally, American Century Companies Inc. acquired a new stake in Trevena in the fourth quarter valued at about $135,000. 56.91% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Trevena Inc (TRVN) Receives Consensus Recommendation of “Buy” from Analysts” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/02/13/trevena-inc-trvn-receives-consensus-recommendation-of-buy-from-analysts.html.

About Trevena

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Analyst Recommendations for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply